enGene (NASDAQ:ENGN) Coverage Initiated by Analysts at Wells Fargo & Company

Wells Fargo & Company assumed coverage on shares of enGene (NASDAQ:ENGN) in a research report sent to investors on Monday morning, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $30.00 target price on the stock.

ENGN has been the subject of a number of other reports. Morgan Stanley began coverage on shares of enGene in a research note on Friday, March 8th. They set an overweight rating and a $40.00 target price for the company. UBS Group assumed coverage on shares of enGene in a research report on Thursday, March 28th. They issued a buy rating and a $37.00 price objective for the company. Leerink Partnrs reaffirmed an outperform rating on shares of enGene in a research report on Tuesday, February 20th. SVB Leerink initiated coverage on enGene in a report on Tuesday, February 20th. They issued an outperform rating and a $31.00 price target for the company. Finally, Guggenheim initiated coverage on enGene in a report on Monday, April 15th. They set a buy rating and a $34.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of Buy and a consensus price target of $34.40.

enGene Price Performance

Shares of ENGN stock opened at $14.80 on Monday. The business’s 50 day simple moving average is $16.11. enGene has a 52-week low of $6.69 and a 52-week high of $43.00.

Insider Activity

In related news, major shareholder De Solidarite Des Travai Fonds sold 47,854 shares of the business’s stock in a transaction that occurred on Monday, April 22nd. The shares were sold at an average price of $15.00, for a total value of $717,810.00. Following the completion of the transaction, the insider now owns 3,036,153 shares of the company’s stock, valued at $45,542,295. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Hedge Funds Weigh In On enGene

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vivo Capital LLC bought a new stake in shares of enGene in the 4th quarter valued at about $6,264,000. Omega Fund Management LLC acquired a new stake in enGene in the fourth quarter valued at approximately $10,441,000. BVF Inc. IL purchased a new position in enGene in the fourth quarter worth $20,777,000. Finally, Fcpm Iii Services B.V. purchased a new position in enGene in the fourth quarter worth $80,097,000. Hedge funds and other institutional investors own 64.16% of the company’s stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.